Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
9 articles
Newest firstBackground/Objectives Corticobasal syndrome (CBS) shows weak clinicopathological correlation, with only half of cases attributable to corticobasal degeneration (CBD). Common alternative aetiologies include Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). Emerging disease modifying therapies are likely to require accurate antemortem differentiation. While plasma biomarkers have potential, clinical…
Open article record in new tab ↗Plasma biomarkers have emerged as powerful tools to identify Alzheimers disease (AD) pathology and are increasingly used for diagnosis and monitoring. However, their wider differential diagnostic and prognostic value in neurodegenerative diseases other than AD remains unclear. This study tested and compared the diagnostic and prognostic performance of neurofilament light chain (NfL), p-tau217, A{beta}42/40 and GFA…
Open article record in new tab ↗Background Synaptic loss is characteristic of many neurodegenerative diseases; it occurs early and is strongly related to functional deficits. Objective In this longitudinal observational study, we determine the rate at which synaptic density is reduced in the primary tauopathies of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), and we test the relationship with disease progression. Meth…
BackgroundPhase three trials of the monoclonal antibodies lecanemab and donanemab, which target brain amyloid, have reported statistically significant differences in clinical endpoints in early Alzheimers disease. These drugs are already in use in some countries and are going through the regulatory approval process for use in the UK. Concerns have been raised about the ability of healthcare systems, including thos…
Open article record in new tab ↗The relationship between in vivo synaptic density and molecular pathology in primary tauopathies is key to understanding the impact of tauopathy on functional decline and in informing new early therapeutic strategies. In this cross-sectional observational study, we determine the in vivo relationship between synaptic density and molecular pathology in the primary tauopathies of progressive supranuclear palsy and co…
Open article record in new tab ↗Understanding the cellular underpinnings of neurodegeneration remains a challenge; loss of synapses and dendritic arborization are characteristic and can be quantified in vivo, with [11C]UCB-J PET and MRI-based Orientation Dispersion Imaging (ODI), respectively. We aimed to assess how both measures are correlated, in 4R-tauopathies of progressive supranuclear palsy - Richardson's Syndrome (PSP-RS; n = 22) and amyl…
Open article record in new tab ↗The relationship between in vivo synaptic density and tau burden in primary tauopathies is key to understanding the impact of tauopathy on functional decline and in informing new early therapeutic strategies. In this cross-sectional observational study, we determine the in vivo relationship between synaptic density and molecular pathology, in the primary tauopathies of Progressive Supranuclear Palsy (PSP) and Cort…
Open article record in new tab ↗ABSTRACT Understanding the cellular underpinnings of neurodegeneration remains a challenge; loss of synapses and dendritic arborisation are characteristic and can be quantified i n vivo , with [ 11 C]UCB-J PET and MRI-based Orientation Dispersion Imaging (ODI), respectively. We aimed to assess how both measures are correlated, in 4R-tauopathies of Progressive Supranuclear Palsy (PSP-RS; n = 22) and amyloid-negativ…
Open article record in new tab ↗Objective Differentiating idiopathic Parkinson's disease from atypical parkinsonian syndromes is challenging, especially in the early stages. We assessed whether the Revised Addenbrooke's Cognitive Examination (ACE-R) could differentiate between parkinsonian syndromes and reflect longitudinal changes in cognition in these disorders. Methods The ACE-R was administered at baseline and after approximately 18 months t…